key: cord-0727035-51urmn2b
authors: Solanich, X.; Padullés, N.; Niubó, J.; Videla, S.; Antolí, A.; Rocamora‐Blanch, G.; Corbella, X.
title: Inhibition of SARS‐CoV‐2 replication using calcineurin inhibitors: are concentrations required clinically achievable?
date: 2021-02-25
journal: J Intern Med
DOI: 10.1111/joim.13264
sha: 222f549e8aae7b08725df875544694eb09b0f00f
doc_id: 727035
cord_uid: 51urmn2b

nan

The authors hypothesize that this beneficial effect may be due to both the anti-inflammatory and the antiviral properties of CsA. Accordingly, they report that, in addition to the well-known role as immunomodulatory agent, CsA shows an interesting certain antiviral activity, inhibiting in vitro the replication of several coronavirus, including SARS-CoV and MERS-CoV. [2] [3] [4] In this regard, we would like to remark that, although calcineurin inhibitors have been shown to inhibit SARS-CoV replication in cell cultures, the 50% effective concentrations (EC 50 ) of CsA in Vero cells have been reported to be 3.3 µM (corresponding to plasma levels of 3968 ng/mL), 2 which is 10fold higher than the recommended therapeutic range in humans, and 6.9 µM (corresponding to plasma levels of 5540 ng/mL) 5 in the case of tacrolimus, which is 1000-fold. Therefore, we agree that the use of CsA might be justified in those severe COVID-19 patients at risk to transit into the second stage of the disease, by blocking the excessive inflammatory response, but not at the early stages, when viral growth and spread occurs. In this regard, we have recently launched a randomized controlled trial (RCT) using tacrolimus to treat severe COVID-19 patients, 6 and we encourage the development of new other RCTs to assess the efficacy and safety of calcineurin inhibitors, at recommended dose, focused on to tackle the systemic host-immune hyperinflammatory response present in severe COVID-19.

All authors declare no competing interests.

No funding was received. 

Cyclosporine A plus low-dose steroid treatment in COVID-19 improves clinical outcomes in patients with moderate to severe disease: a pilot study

The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors

Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia

Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study

Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506

Pragmatic, open-label, single-center, randomized, phase II clinical trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus in patients with severe pneumonia secondary to COVID-19: The TACRO-VID trial protocol